The company’s corporate controller, Len Ross, will become the principal financial and accounting officer.
Paul Ashton, president and CEO of pSivida, said: “The company and the board of directors would like to thank Mike for his many contributions. During the past year we completed our reincorporation in the US and the listing of our common stock on Nasdaq.
“With these major milestones achieved we are now structured effectively to continue to advance the evolution of miniaturized injectable drug delivery devices for use in ophthalmology and the treatment of other localized and systemic diseases. We wish Mike the best of luck in his future endeavors.”